Literature DB >> 9524095

Aggressive treatment with complete remission in primary diffuse leptomeningeal gliomatosis--a case report.

P Beauchesne1, J Pialat, R Duthel, F G Barral, G Clavreul, T Schmitt, B Laurent.   

Abstract

Primary leptomeningeal gliomatosis is rare, and the diffuse form (PLDG) is even more unusual. The following report is an example. A 17 year-old man developed a syndrome characterized by extensive basal and chronic spinal meningitis. Routine biological tests showed elevated levels of CSF proteins, and moderate mononuclear pleocytosis, with no direct evidence of neoplasia, leading to a diagnosis of chronic meningitis. A second meningeal biopsy, guided by MRI and performed in the left frontal region, led to the specific diagnosis of primary diffuse leptomeningeal gliomatosis. Treatment including ventricular and lumbar shunting, a course of cortico-spinal radiation, and three courses of an eight-drug systemic chemotherapy with intrathecal methotrexate lead to complete remission over 15 months. We believe that this is the first report of such a remission in the literature.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9524095     DOI: 10.1023/a:1005888319228

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  27 in total

1.  Oligodendrogliomatosis with intracranial hypertension.

Authors:  J KOREIN; I FEIGIN; M F SHAPIRO
Journal:  Neurology       Date:  1957-08       Impact factor: 9.910

2.  Spinal subarachnoid metastasis from primary intracranial glioblastoma multiforme.

Authors:  S S Erlich; R L Davis
Journal:  Cancer       Date:  1978-12       Impact factor: 6.860

3.  Primary leptomeningeal gliomatosis with predominant involvement of the spinal cord.

Authors:  N Heye; J R Iglesias; K Tönsen; G Graef; K Maier-Hauff
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

Review 4.  Primary diffuse leptomeningeal gliomatosis with anaplastic features.

Authors:  M T Giordana; G B Bradac; C A Pagni; S Marino; A Attanasio
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

5.  Primary leptomeningeal oligodendroglioma: case report.

Authors:  L R Rogers; M L Estes; S A Rosenbloom; L Harrold
Journal:  Neurosurgery       Date:  1995-01       Impact factor: 4.654

6.  Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy.

Authors:  T W Pendergrass; J M Milstein; J R Geyer; A F Mulne; E J Kosnik; J D Morris; R L Heideman; F B Ruymann; J T Stuntz; W A Bleyer
Journal:  J Clin Oncol       Date:  1987-08       Impact factor: 44.544

7.  Primary diffuse leptomeningeal gliomatosis.

Authors:  P Bailey; Y Robitaille
Journal:  Can J Neurol Sci       Date:  1985-08       Impact factor: 2.104

8.  Diffuse leptomeningeal gliomatosis: report of three cases.

Authors:  H T Whelan; J H Sung; A R Mastri
Journal:  Clin Neuropathol       Date:  1987 Jul-Aug       Impact factor: 1.368

9.  Gadolinium-DTPA in spinal disease.

Authors:  G Sze
Journal:  Radiol Clin North Am       Date:  1988-09       Impact factor: 2.303

10.  Chronic meningitis: the role of meningeal or cortical biopsy.

Authors:  T M Cheng; B P O'Neill; B W Scheithauer; D G Piepgras
Journal:  Neurosurgery       Date:  1994-04       Impact factor: 4.654

View more
  11 in total

1.  Temozolomide-induced partial response in a patient with primary diffuse leptomeningeal gliomatosis.

Authors:  Enrico Franceschi; Giovanna Cavallo; Luciano Scopece; Roberta Degli Esposti; Gabriele Paioli; Anna Paioli; Emanuela Palmerini; Maria Pia Foschini; Anna Federica Marliani; Lucio Crinò
Journal:  J Neurooncol       Date:  2005-07       Impact factor: 4.130

2.  A case report and review of the literature.

Authors:  Shoji Yomo; Tsuyoshi Tada; Shuichi Hirayama; Naoko Tachibana; Masako Otani; Yuichiro Tanaka; Kazuhiro Hongo
Journal:  J Neurooncol       Date:  2006-09-20       Impact factor: 4.130

3.  Primary diffuse leptomeningeal gliomatosis in 2 dogs.

Authors:  Sara Canal; Marco Bernardini; Silvia Pavone; Maria T Mandara
Journal:  Can Vet J       Date:  2013-11       Impact factor: 1.008

4.  Leptomeningeal gliomatosis as the initial presentation of gliomatosis cerebri.

Authors:  Matthew K Knox; Cynthia Ménard; Warren P Mason
Journal:  J Neurooncol       Date:  2010-02-10       Impact factor: 4.130

Review 5.  The leptomeninges as a critical organ for normal CNS development and function: First patient and public involved systematic review of arachnoiditis (chronic meningitis).

Authors:  Carol S Palackdkharry; Stephanie Wottrich; Erin Dienes; Mohamad Bydon; Michael P Steinmetz; Vincent C Traynelis
Journal:  PLoS One       Date:  2022-09-30       Impact factor: 3.752

6.  Disseminated primary diffuse leptomeningeal gliomatosis: a case report with liquid based and conventional smear cytology.

Authors:  Masha Bilic; Cynthia T Welsh; Zoran Rumboldt; Rana S Hoda
Journal:  Cytojournal       Date:  2005-09-20       Impact factor: 2.091

7.  Primary diffuse leptomeningeal gliomatosis: An autopsy case report.

Authors:  Shaik Afshan Jabeen; Arikapadu Haritha Chowdary; Rukmini Mridula Kandadai; Megha S Uppin; Angamattu Kanikannan Meena; Rupam Borgohain; Challa Sundaram
Journal:  Ann Indian Acad Neurol       Date:  2014-04       Impact factor: 1.383

8.  Primary diffuse leptomeningeal oligodendrogliomatosis: A case report and literature review.

Authors:  Amarnath Chellathurai; Jay S Vaidya; Gopinathan Kathirvelu; Periakaruppan Alagappan
Journal:  Indian J Radiol Imaging       Date:  2016 Jul-Sep

9.  Primary Diffuse Leptomeningeal Gliomatosis: Radiological/Pathological Features.

Authors:  Ehtasham Ahmad; Mohamed Mohamed; Apostolos Vrettos
Journal:  Case Rep Neurol Med       Date:  2016-11-07

Review 10.  A polycystic variant of a primary intracranial leptomeningeal astrocytoma: case report and literature review.

Authors:  Antonio De Tommasi; Giuseppe Occhiogrosso; Claudio De Tommasi; Sabino Luzzi; Antonella Cimmino; Pasqualino Ciappetta
Journal:  World J Surg Oncol       Date:  2007-06-23       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.